• About
  • Advertise
  • Careers
  • Contact
  • Write for us
No Result
View All Result
Thursday, January 21, 2021
THE MILLENNIAL SOURCE
  • World
  • US
  • Asia
  • Politics
  • Business
  • Profiles
  • Lifestyle
    • Food & Travel
    • Tech & Money
    • Health
    • Entertainment
  • Newsletter
TMS
No Result
View All Result
Home WORLD

US government agrees to pay Pfizer US$1.95 billion for 100 million doses of COVID-19 vaccine

byAnanta Agarwal
July 22, 2020
in WORLD
Reading Time: 3 minute read
US government agrees to pay Pfizer US$1.95 billion for 100 million doses of COVID-19 vaccine

Source: Reuters

Share on FacebookShare on TwitterShare on Linkedin



On Wednesday, the United States government released a statement announcing a US$1.95 billion dollar contractual agreement with pharmaceutical company Pfizer Inc. and German biotechnology company BioNTech SE to obtain 100 million doses of a COVID-19 vaccine.

Both companies will have to first complete a large Phase 3 clinical trial, set to begin this month, to test the effectiveness of the vaccine in protecting individuals against the virus. 

If the trial is successful, the companies expect to receive emergency use authorization by the Food and Drug Administration (FDA) as early as October 2020. 

By the end of 2020, the companies expect to manufacture at least 100 million doses, subject to regulatory approval. The doses will be received by the US government for US$1.9 billion, or US$20 per dose, as per the agreement. 

“Depending on success in clinical trials, today’s agreement will enable the delivery of approximately 100 million doses of this vaccine to the American people,” Health Secretary Alex Azar said in the statement.

The agreement also gives the US the rights to order up to 500 million more doses of the vaccine. 

The vaccines are expected to be provided to Americans free of cost.

“We’ll price our potential vaccine consistent with the urgent global emergency that we’re facing,” John Young, the Chief Business officer of Pfizer, said at a House Committee on Energy and Commerce hearing on Tuesday, adding, “A vaccine is meaningless if people are unable to afford it.” 

Executives from five other vaccine manufacturing companies also participated in the hearing. 

Following the announcement on Wednesday, Pfizer’s shares rose by five percent in premarket trading. BioNTech’s shares also rose by five percent. 

The agreement is part of the Trump administration’s Operation Warp Speed initiative to secure COVID-19 vaccines for Americans. 

Under the agreement, the administration provided US$1.2 billion to British-Swedish drug company AstraZeneca to make Oxford University’s COVID-19 vaccine. 

The administration also provided US$483 million to Massachusetts biotech company Moderna for its vaccine development.

AstraZeneca recently released data indicating that the participants who were administered the Oxford vaccines in its early trials were able to develop neutralizing antibodies similar to those found in COVID-19 survivors, with only minor side effects. 

However, Pfizer received no funding for its vaccine development. It will only receive payment by the US government for its doses and distribution, provided the vaccine is approved. 

Young stated in the House Committee on Energy and Commerce hearing that the company refused federal funding in order to skip time on contractual negotiations. 

“We didn’t accept the federal government funding solely for the reason that we wanted to be able to move as quickly as possible with our vaccine candidate into the clinic.”

Dr. Albert Bourla, Pfizer’s Chairman and CEO, said in the statement that “We’ve been committed to making the impossible possible by working tirelessly to develop and produce in record time a safe and effective vaccine to help bring an end to this global health crisis.”

Bourla went on to add, “We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that product would be available immediately if our clinical trials prove successful and an Emergency Use Authorization is granted. We are honored to be a part of this effort to provide Americans access to protection from this deadly virus.”

Have a tip or story? Get in touch with our reporters at [email protected]

Like TMS? Subscribe to our free daily newsletter

Related

Tags: BusinessNorth AmericaShort read
ShareTweetShare

Latest Posts

Telegram is becoming a new haven for QAnon, even as Trump leaves office

Telegram is becoming a new haven for QAnon, even as Trump leaves office

January 21, 2021
Biden’s first 100 days, explained

Biden’s first 100 days, explained

January 20, 2021
“Economic anxiety” is an insufficient explanation for Donald Trump’s presidency

“Economic anxiety” is an insufficient explanation for Donald Trump’s presidency

January 20, 2021

What is Poshmark, the secondhand retail app going public?

January 20, 2021

Will a Democratic Senate abolish the filibuster?

January 19, 2021

What is Biden’s plan to vaccinate America?

January 19, 2021

What consequences are Trump supporters facing for the attack on the Capitol?

January 19, 2021

Does deplatforming work?

January 18, 2021

The international reaction to Trump’s Twitter ban, explained

January 18, 2021
  • About
  • Advertise
  • Careers
  • Contact
  • Write for us

© 2020 The Millennial Source Ltd.

No Result
View All Result
  • World
  • US
  • Asia
  • Politics
  • Business
  • Profiles
  • Lifestyle
    • Food & Travel
    • Tech & Money
    • Health
    • Entertainment
  • Newsletter

© 2020 The Millennial Source Ltd.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

The Millennial Source
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.